MENU
RYTM
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

Rhythm Pharmaceuticals (RYTM) Earnings Date & Reports

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases... Show more

Industry: #Biotechnology
A.I. Advisor
published Earnings

RYTM is expected to report earnings to rise 19.20% to -72 cents per share on March 03

Rhythm Pharmaceuticals RYTM Stock Earnings Reports
Q4'26
Est.
$-0.73
Q3'26
Beat
by $0.07
Q2'26
Beat
by $0.08
Q1'26
Est.
$-0.83
Q4'25
Beat
by $0.09
The last earnings report on November 03 showed earnings per share of -61 cents, beating the estimate of -68 cents. With 448.63K shares outstanding, the current market capitalization sits at 7.73B.
A.I.Advisor
Nov 03, 2026

Rhythm Pharmaceuticals (RYTM) Q3 2026 Earnings Recap: A Fast Start to Its Biggest Launch Yet

Key Takeaways

  • Rhythm Pharmaceuticals reported third-quarter 2026 revenue of $92.1 million, up roughly 80% from $51.3 million a year earlier, beating the consensus estimate by about 9%.
  • Net loss narrowed to $41.4 million, or $0.61 per share, compared with a loss of $0.82 per share in the prior-year period and a consensus loss estimate of $0.68 per share.
  • The surge was driven by the U.S. launch of IMCIVREE for acquired hypothalamic obesity (HO), a rare condition causing severe, rapid weight gain after damage to the hypothalamus region of the brain.
  • Management highlighted more than 700 patient start forms since the late-March approval, with a broadening base of over 500 prescribers.
  • The company also launched IMCIVREE in Japan in October and outlined plans to advance its next-generation oral therapy, bivamelagon, into Phase 3 trials.
  • For more context on this ticker, explore Major News, Today's Price Move, Price Targets, and Forecast pages.
  • For automated, data-driven trade ideas across the market, explore the Trending AI Robots.

Earnings Context and Why It Matters

This report marked Rhythm Pharmaceuticals' second full quarter since the U.S. Food and Drug Administration (FDA) approved IMCIVREE for acquired hypothalamic obesity on March 19, 2026. The launch is a pivotal moment for the company, which is expanding beyond its established Bardet-Biedl Syndrome (BBS) business into a larger, largely untreated patient population. Because acquired HO had no previously approved therapy, investor attention centered on early demand signals, reimbursement trends, and prescriber breadth. The quarter also carried strategic weight beyond the income statement: Rhythm amended its licensing agreement with LG Chem and outlined next-generation drug development plans, signaling its confidence in the broader melanocortin-4 receptor (MC4R) pathway, a key regulator of hunger and weight.

Reported Results

Rhythm Pharmaceuticals reported third-quarter 2026 net product revenue of $92.13 million, up from $51.3 million in the third quarter of 2025, driven primarily by the U.S. launch of IMCIVREE for acquired HO. This exceeded the Zacks Consensus Estimate by 9.07%. Net loss attributable to common stockholders was $42.4 million, or $0.61 per basic and diluted share, compared with a loss of $54.3 million, or $0.82 per share, in the prior-year quarter. The loss per share was narrower than the $0.68 consensus estimate, an earnings surprise of roughly 10%. For the nine months ended September 30, 2026, net product revenue reached $223.5 million, up from $137.5 million a year earlier.

On the expense side, research and development (R&D) spending rose modestly year over year, while selling, general, and administrative (SG&A) costs increased more sharply to support the U.S. and Japanese launches. For full-year 2026, Rhythm guided to approximately $360 million to $380 million in non-GAAP operating expenses and said its cash position is sufficient to fund operations for at least 24 months.

AI Screener

Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool that helps traders and investors filter the market using technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs with customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening, making it a useful complement to fundamental research on names like Rhythm Pharmaceuticals. Consider exploring the AI Screener to identify opportunities that match your own criteria.

Market Reaction and Investor Sentiment

Despite the revenue and earnings beats, Rhythm Pharmaceuticals shares traded lower in premarket action following the announcement, according to market reports, reflecting a broader pattern in which strong operational results did not immediately translate into share-price gains. The stock has declined roughly 12.7% since the start of 2026, compared with a gain in the broader market, underscoring investor caution around launch execution, elevated commercial spending, and the competitive landscape in the obesity and rare-disease space. Sentiment heading into the print had been mixed: bulls pointed to accelerating start forms and favorable reimbursement, while bears focused on rising operating costs and the pace of conversion from patient start forms to actual revenue.

Forward Outlook and Key Factors to Monitor

Looking ahead, investors will be watching whether Rhythm can sustain the early momentum of its acquired HO launch in the U.S. and replicate it internationally. The Japan launch, which began on October 14, 2026, represents a meaningful new revenue stream, with management estimating a patient population of 5,000 to 8,000 and reporting early commercial patients already on treatment.

Reimbursement will remain a central theme. The company reported positive IMCIVREE policies covering approximately 60% of Medicaid-covered lives and 75% of commercial-covered lives for acquired HO, and further policy adoption is expected through year-end. The speed at which patient start forms convert into paid prescriptions will be a key indicator of revenue durability.

On the pipeline front, Rhythm plans to initiate a Phase 3 study of bivamelagon, its daily oral MC4R agonist, in acquired HO, with screening expected to begin by the end of 2026 and first dosing in January 2027. A separate Phase 3 program in Prader-Willi syndrome is targeted for 2027. The amended LG Chem agreement, which reduces future royalty rates on MC4R portfolio sales to 1% in exchange for a $350 million payment, is intended to align development incentives and improve long-term economics.

Finally, cost discipline will be closely watched, given the substantial increase in SG&A spending tied to launch activities. Management's ability to balance top-line growth against rising expenses, while advancing its pipeline and international expansion, will shape how investors evaluate the company's path toward profitability in the quarters ahead.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of peptide therapeutics for metabolic diseases

Industry Biotechnology

Industry
Biotechnology
Address
222 Berkeley Street
Phone
+1 857 264-4280
Employees
414
Web
https://www.rhythmtx.com